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Objective: We sought to bioengineer a nonimmunogenic tracheal tubular matrix of 6 cm in length and test its
structural, functional, and immunologic properties in vitro and in vivo.
Methods: Twelve-centimeter tracheal segments were harvested from Yorkshire boars. Half of each segment was
subjected to a detergent–enzymatic method (containing sodium deoxycholate/DNase lavations) of decellulariza-
tion for as many cycles as needed, and the other half was stored in phosphate-buffered saline at 4C as a control.
Bioengineered and control tracheas were then implanted in major histocompatibility complex–unmatched pigs
(allograft) or mice (xenograft) heterotopically for 30 days. Structural and functional analysis and immunostaining
were performed after each detergent–enzymatic method cycle and transplantation.
Results:Compared with control tracheas, bioengineered matrices displayed no major histocompatibility complex
class I and II antigens after 17 detergent–enzymatic method cycles, without significant (P> .05) differences in
their strain ability (rupture force, 56.1  3.3 vs 55.5  2.4 N; tissue deformation at 203%  13% vs 200%
 8% or 12.2  0.8 vs 12  0.5 cm; and applied maximum force, 173.4  3.2 vs 171.5  4.6 N). Thirty
days after implantation, significantly (P< .01) smaller inflammatory reactions (392 vs 15 macrophages/mm2
and 874 vs 167 T lymphocytes/mm2) and P-selectin expressions (1/6 vs 6/6) were observed in both the xenograft
and allograft models with bioengineered matrices compared with those seen with control tracheas. There was no
development of anti-pig leukocyte antigen antibodies or increase in both IgM and IgG content in mice implanted
with bioengineered tracheas.
Conclusions: Bioengineered tracheal matrices displayed similar structural and mechanical characteristics to na-
tive tracheas and excite no immune response to 30 days when implanted as allografts or xenografts. This method
holds great promise for the future of tissue-engineered airway replacement.Tracheal resection with primary reconstruction is the only
curative treatment in patients with a variety of benign or ma-
lignant tracheal lesions.1 Unfortunately, the resectable
length of the diseased trachea is usually restricted to approx-
imately 30% of the total length in children and around 6 cm
in adults, and any further increase in this resection rate
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This last is not yet clinically available because almost every
attempt to provide an autologous or synthetic safe and repro-
ducible tracheal graft has been disappointing thus far,1
casting doubt on the future of long-segment tracheal replace-
ment.3
Tissue bioengineering has emerged as the most promis-
ing technique to create a near-normal trachea,1,4 and
encouraging early experimental results5 and clinical appli-
cations6 have been reported. However, the bioengineering
process in these previous experiences was labor intensive
and required too many steps to gain wide clinical accep-
tance. Thus, and encouraged by our recent in vitro gener-
ation of short but vital tracheal matrices,7 we aimed to
study bioengineered tubular tracheal matrices of at least 6
cm in length and evaluate their outcome without immuno-
suppression in allograft and xenograft animal heterotopic
models.
MATERIALS AND METHODS
Donor and recipient pigs were 25 outbred Yorkshire Duroc boars (Iso-
quimen S/L, Barcelona, Spain) weighing 42.4  3.3 kg. Sixteen CD-1
mice (Charles River Laboratories Italia S.r.l., Calco, Italy) also acted as re-
cipients. All animals received care in compliance with the ‘‘Principles ofgery c September 2009
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DEM ¼ detergent–enzymatic method
MHC ¼ major histocompatibility complex
PBS ¼ phosphate-buffered saline
SLA ¼ swine leukocyte antigen
laboratory animal care’’ formulated by the National Society for Medical Re-
search and the ‘‘Guide for the care and use of laboratory animals’’ prepared
by the Institute of Laboratory Animal Resources, National Research Coun-
cil, and published by the National Academy Press, revised 1996. The study
was approved by the Animal Care and Use Committee and the Bioethics
Committee of the University of Barcelona.
Study Design
Twelve-centimeter tracheal segments were harvested from donor pigs.
Half of each was allocated to the bioengineering protocol previously de-
scribed,7 and half was stored as a control. Structural and morphologic stud-
ies were performed. When no major histocompatibility complex (MHC)
could be detected, decellularization cycles ceased, and donor tracheal seg-
ments were implanted heterotopically into either MHC–unmatched pigs
or mice (Figure 1). Biopsy specimens and blood samples were taken from
recipient animals weekly until 30 days after implantation.
Anesthesia and Tracheal Harvesting
Pigs (n ¼ 13) were premedicated with intramuscular azaperone (4 mg/
kg; Esteve S.A., Barcelona, Spain) and intravenous thiopental (10 mg/kg;
B. Braun Medical S.A., Rubi, Barcelona, Spain) and relaxed with intra-
venous vecuronium (6 mg $ kg1 $ h1; Norcuron, Organon S.A., Barce-
lona, Spain). Orotracheal intubation was performed through a 7.5F
endotracheal tube under bronchoscopic guidance. Anesthesia was main-
tained by means of continuous infusion of fentanyl (1 mg$ kg1 $ h1;
B. Braun Medical S.A.) and propofol (3-5 mg$ kg1 $ h1; B. Braun Med-
ical S.A.). Peripheral oxygen arterial saturation was permanently moni-
tored with a pulse oximeter (BCI, Inc, Waukesha, Wis) placed at the
pig’s tail. A lower median cervicotomy permitted dissection of the entire
trachea, as previously described.8-10 Then death was induced by using an
intravenous bolus of fentanyl, propofol, and potassium chloride (40 mEq;
B. Braun, Melsungen, Germany). On extubation, the trachea from the firstThe Journal of Thoracic and Cring to the carina was harvested under sterile conditions. Pigs were then
killed by using an approved method (overdose of intravenous anesthetic
agent).
The harvested segment was then divided into two 6-cm halves. One
half (control) was placed in a stock solution made of phosphate-buffered
saline (PBS; Invitrogen S.A., Barcelona, Spain), containing 1% antibi-
otic and antimycotic solution (AA; Sigma Chemical Company, Barce-
lona, Spain). The other half was similarly stored for 24 hours but then
submitted to the bioengineering protocol, as below. Additionally, small
sections were stored at80C for immunohistology as a baseline native
control.
Matrix Bioengineering
The overlying tissue of the harvested tracheas was stripped off, deprived
of trachealis muscle, and rinsed 4 times (for 4 hours each) in PBS containing
1% antibiotic and antimycotic solution. Thereafter the protocol continued
as previously reported.7 Briefly, tissue was processed with multiple treat-
ment cycles, including the following steps: tissue was stored in Aqua milliQ
(Millipore, Madrid, Spain) for 48 hours at 4C and then incubated in 4%
sodium deoxycholate for 4 hours and 2000 kU of DNase-I in 1 mol/L
NaCl (Sigma Chemical Company) for 4 hours. The samples were stored
in PBS (containing 1% antibiotic and antimycotic) at 4C up to a maximum
of 2 months. The presence of cellular elements and MHCþ cells were veri-
fied histologically after each cycle.
Matrix Histology and Immunochemistry
Samples were washed thoroughly in saline before use. To quantify the
remaining cells after each cycle of the detergent–enzymatic method
(DEM) treatment, we analyzed 10 slides with an optical microscope. The
samples were covered with Vectashield (Vector Laboratories, Inc, Burlin-
game, Calif) mounting medium for fluorescence with 40-6-diamidino-2-phe-
nylindole (Vector Laboratories, Inc), and the total number of nuclei was
visualized at 2503 magnification by using fluorescence microscopy. The
cell density was expressed as the number of nuclei 3 105/mm2. The mean
 1 standard deviation (SD) was determined for each cycle analysis. Par-
affin-embedded tissue sections measuring 5 mm were mounted on slides
and stained with hematoxylin and eosin (Merck, Darmstadt, Germany) to
evaluate morphologic changes. The presence of MHC markers was evalu-
ated by means of immunostaining. After each DEM cycle, we fixed aliquots
of the trachea with 10% neutral buffered formalin for 24 hours and embed-
ded on paraffin. Vertical sections were incubated for 30 minutes at room
temperature with PBS containing 10% fetal calf serum (Invitrogen S.A.).FIGURE 1. Study design. The term native trachea represents natural untreated tracheas harvested from healthy animals. DEM, Detergent–enzymatic
method; control trachea, native trachea.ardiovascular Surgery c Volume 138, Number 3 587
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anti-MHC class I OX27 and anti-MHC class II OX4 antibodies (Abcam,
Cambridge, United Kingdom) diluted in 1% fetal calf serum–PBS
(1:400), and then labeled with the avidin/biotin–amplified immunoperoxi-
dase method by using the Large Volume Dako LSAB Peroxidase Kit
(Dako, Glostrup, Denmark). A biotinylated goat anti-mouse antibody
(HþL; Vector Laboratories, Inc) served as a secondary antibody. Streptavi-
din–peroxidase conjugate was applied, and final staining was performed
with diaminobenzidine slides and counterstained with hematoxylin. For
fluorescence microscopy, a fluorescein isothiocyanate–conjugated second-
ary antibody was used.
Physical Strain Tests
Both native tracheas and bioengineered matrices were tested for
mechanical properties after varyingnumbersof cycles ofDEM. We useda ten-
sile-test device (Zwick/Roell, version Z0.5TS, Barcelona, Spain) able to de-
termine tensile stress under varying rates of strain or elongation with
a precision of 0.0001 N and 0.001 mm in force and position, respectively.
Each sample was subjected to increasing uniaxial tensile testing until rupture,
which was confirmed by the loss of load and the appearance of tears in the tis-
sue. After clamping the specimen into sample holders, a preload (preliminary
force) of 2N was applied, and thereafter, the tensile trial started at a constant
elongation rate of 1 mm/s at room temperature. The tensile tester recorded in
real time the load and elongation to which the tissue was subjected.
Matrix Implantation as an Allograft in Pigs
The recipient animals (n¼ 12) were randomly assigned (by using a com-
puter-generated code) to one of 2 different groups receiving the
bioengineered matrices or native control tracheas. Animals were anesthe-
tized as above, and the groin region was prepared. Tracheal samples were
implanted subcutaneously, and their proximal and distal lumens were
anchored to the surrounding skin to leave them open.9 Postoperatively, an-
tibiotics (cefazolin, 2 g administered intravenously; Lilly, Madrid, Spain)
and analgesics (Enantyum, 40 mg/12 hours; Menarini, Barcelona, Spain)
were administered intravenously. Animals were examined daily for 30
days for clinical signs of inflammation or rejection and for general health.
Weekly general anesthetic endoscopies were performed to biopsy-im-
planted matrices and surrounding host tissue, as well as to take blood sam-
ples to check for the development of antibodies and increased inflammatory
response. Thirty days after implantation, animals were killed as above, and
the matrices were harvested with a cuff of donor tissue.
TABLE 1. In vitro morphologic and immunologic evaluation of native
and bioengineered tracheas
Bioengineered matrices
(no. of DEM cycles)
Characteristics
Native
trachea 10th 17th 20th
Morphologic diameter (cm):
Transversal 1.6  0.1 1.6  0.1 1.5  0.1 1.5  0.2
Saggital 2.1  0.1 2.1  0.1 2.0  0.1 1.9  0.2
Length (cm) 6.0  0.3 6.0  0.2 6.0  0.2 5.9  0.3
Nuclei 3 105 mm2 298  42 152  47* 53  9* 15  4*
Chondrocytes’ cell walls þþþ þ  –
Immunologic
MHC class II þþþ þ  
MHC class I þþþ þ  
The term native trachea represents natural untreated tracheas harvested from healthy
animals. DEM, Detergent–enzymatic method; MHC, major histocompatibility com-
plex;þþþ, very high expression;þ, low expression; –, not expressed. *P< .01 versus
native trachea.588 The Journal of Thoracic and Cardiovascular SuMatrix Implantation as a Xenograft in Mice
Mice (n ¼ 16) were anesthetized with isoflurane (Halocarbon Laborato-
ries, River Edge, NY). Matrix samples (1.53 1.5 cm) were implanted under
the dorsal skin. Mice receiving the matrices were killed on days 7, 15, 23,
and 30. Blood samples were taken, and tissue samples were analyzed
both macroscopically and microscopically.
Analysis of Tissue From Pig Recipients
Samples were formalin fixed and paraffin embedded before staining with
hematoxylin and eosin (Merck).
Anti–swine leukocyte antigen (anti-SLA) antibodies were tested at 7, 15,
23, and 30 days after matrix implantation by using a modification of the
standard flow cytometric crossmatch on lymph node cells, as previously
described.11 Briefly, donor pig lymph node cells were incubated for 30
minutes with recipient serum and rinsed 3 times in PBS, and a fluores-
cein-marked anti-porcine–immunoglobulin and phycoerythrin-marked
anti-porcine CD3 were added for 30 minutes. A FACS-Scan (FACSAria;
Becton–Dickinson, Erembodegem, Belgium) was used to evaluate the dou-
ble fluorescence. The coefficient between the mean channel in test serum
and the negative control serum for T cells (defined by mentioned double
fluorescence) was recorded. We considered a ratio of greater than 2.9 as pos-
itive based on previous samples obtained before implantation. To identify T
lymphocytes, monocytes/macrophages, and polymorphonuclear granulo-
cytes, immunochemistry was performed with a rabbit anti-CD3 antibody
(Dako) and mouse anti-L1 antibody (Dako), respectively.
P-selectin (CD62P) expression was measured in animals by fixing ma-
trix/native trachea connective blood vessels after 30 days with 2% parafor-
maldehyde for 3 hours (4C) before immersing them in OCT medium and
freezing in liquid nitrogen. Thereafter, sections were fixed in paraformalde-
hyde (4%), and the primary antibody (P-sel.KO.2.5) was incubated for 2
hours at room temperature. Negative controls were carried out similarly
but omitting the primary antibody. A piece of harvested tissue was stimu-
lated with lipopolysaccharides (Sigma Chemical; 30 mg/kg) and used as
a positive control. The secondary antibody (Cy3 goat anti-mouse IgG; Jack-
son Immuno Research Laboratories, West Grove, Pa) was incubated for 1
hour at room temperature, and sections were mounted with Fluorescent
Mounting Medium PCK (Dako). Finally, samples were analyzed by means
of confocal microscopy (Leica TCS NT, Heidelberg, Germany), and the
quantity of P-selectin was defined as low or high expression based on a com-
puter-added system.
Analysis of Tissue From Murine Recipients
Tissue samples were immersed in 10% buffered formalin for 24 hours
and embedded in paraffin. Then sections were stained with hematoxylin
and eosin (Merck) and examined for the presence of inflammatory cells.
Blood samples from mice were analyzed to identify levels of total circulat-
ing IgG and IgM (in milligrams per milliliter) with an enzyme-linked immu-
nosorbent assay kit (ZeptoMetrix, Buffalo, NY).
Statistical Analysis
Continuous variables were compared by using the independent-samples
t test. The odds ratio was calculated to perform between-group comparisons
of categorical variables. Results are presented as means  standard devia-
tions of the mean. Analyses were made with the SPSS package (version
12.0; SPSS, Inc, Chicago, Ill).
RESULTS
In Vitro Evaluation
The bioengineering process lasted 35  1, days, corre-
sponding to 17 DEM cycles, after which the bioengineered
tracheal matrices showed few residual nuclei of chondro-
cytes but a complete removal of MHC class I and IIrgery c September 2009
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SFIGURE 2. Transverse sections of native trachea (A–D) and tracheal matrices (E–H) after 17 cycles of detergent–enzymatic treatment immunostained with
40-6-diamino-2-phenylindole for nuclei (A, C, E, and G) or with monoclonal anti-MHC class I (B and F) and II (C and H). Neither MHC class I– nor MHC
class II–presenting cells were detected in the bioengineered matrices. The term native trachea represents natural untreated tracheas harvested from healthy
animals.antigens. By contrast, MHC class I and II expression was
ubiquitous in control tracheas (Table 1 and Figures 2–4,
A). The bioengineered tracheas showed no significant differ-
ences in their strain ability compared with control tracheas
until the 17th cycle (Table 2 and Figure 4, B). However,
a higher (18 cycles) number of DEM cycles led to a lossThe Journal of Thoracic and Cof the matrices’ properties. The mechanical properties of
the bioengineered tracheas were similar to those of the na-
tive tracheas, and there was no influence of airway diameter
on the maximum breaking force. The breaking point for all
tracheas was observed at the intercartilaginous septa as hor-
izontal fissures with preservation of the physiologic tissueardiovascular Surgery c Volume 138, Number 3 589
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SFIGURE 3. Transverse sections of native trachea (A) and tracheal matrices (B) after 17 cycles of detergent–enzymatic treatment stained with hematoxylin
and eosin. (Original magnification3200.) Seventeen cycles were not able to completely decellularize tracheal specimens, and nuclei were still visible inside
the cartilage ring, whereas cell walls disappeared by comparison with the native trachea. Arrows indicate intact chondrocytes in native trachea or nuclei with
absent cell walls in bioengineered matrices. The term native trachea represents natural untreated tracheas harvested from healthy animals.FIGURE 4. A, Remaining nuclei of chondrocytes during the bioengineering procedure. *P<.01 versus native trachea. The line within the box corresponds
with the median, and the lined border corresponds with the standard deviation. B, A box plot of the maximum force comparing native with bioengineered
matrices. *P<.01 versus native trachea. NS, Nonsignificant differences compared with native trachea. The line within the box corresponds with the median,
and the lined border corresponds with the standard deviation. NT, Native tracheas. The term native trachea represents natural untreated tracheas harvested
from healthy animals.TABLE 2. Comparison of the mechanical characteristics of native and bioengineered tracheas
Bioengineered matrices (no. of DEM cycles)
Characteristics Native trachea 10th 17th 20th
Mechanical
Maximum force (N) 173.4  3.2 189.1  8.8 171.5  4.6 162.4  8.5y
Rupture force (N) 56.1  3.3 55.5  1.8 55.5  2.4 48.2  3.1y
Tracheal rupture point (cm) 12.2  0.8 12.1  0.5 12  0.5 8.6  1.2y
Tissue deformation (%) 203  13 202  9 200  8 146  15*
The term native trachea represents natural untreated tracheas harvested from healthy animals. DEM, Detergent–enzymatic method; Maximum force, applied maximum force;
N, Newton. *P< .01 versus native trachea. yP< .05 versus native trachea.
TABLE 3. In vivo evaluation of the bioengineered tracheal matrices implanted heterotopically in HLA-unmatched pigs
Characteristics
Postimplantation day 7th, NT vs BM 15th, NT vs BM 23th, NT vs BM 30th, NT vs BM
Macrophages/mm2 125  51 vs 13  9* 262  53 vs 15  5* 310  47 vs 16  6* 392  43 vs 15  6*
T lymphocytes/mm2 200  85 vs 152  43* 367  121 vs 160  55* 655  291 vs 158  57* 874  289 vs 167  55*
SLA antibodies 0/6 vs 0/6 0/6 vs 0/6 1/6 vs 0/6 6/6 vs 0/6*
P-selectin expression 0/6 vs 0/6 1/6 vs 0/6 3/6 vs 1/6y 6/6 vs 1/6y
NT, native tracheas; BM, bioengineered matrices; SLA antibodies, anti–swine leukocyte antigen; x/6, expressed in n¼ x of all pigs. *P<.01 versus native trachea at the same time
point. yP< .05 versus native trachea at the same time point.590 The Journal of Thoracic and Cardiovascular Surgery c September 2009
Jungebluth et al General Thoracic SurgeryTABLE 4. In vivo evaluation of bioengineered tracheal matrices implanted heterotopically in mice
Characteristics
Postimplantation day 7th, NT vs BM 15th, NT vs BM 23th, NT vs BM 30th, NT vs BM
Macrophages/mm2 111  36 vs 10  6* 202  29 vs 13  7* 278  60 vs 16  8* 341  45 vs 17  8*
T lymphocytes/mm2 199  76 vs 145  46* 297  98 vs 140  44* 595  203 vs 144  39* 855  178 vs 141  33*
WBCs 3 103/mm3 43  13 vs 13  4* 51  17 vs 15  3* 58  17 vs 14  4* 63  18 vs 12  2*
IgM serum (mg/mL) 2.13  0.25 vs 0.56  0.11* 2.11  .4 vs 0.51  0.2* 1.51  0.3 vs 0.48  0.12* 0.75  0.35 vs 0.47  .21y
IgG serum (mg/mL) 8  4 vs 8  2 9  4 vs 8  3 19  5 vs 10  4y 25  6 vs 10  3*
NT, Native tracheas; BM, bioengineered matrices; WBC, white blood cells. *P< .01 versus native trachea at the same time point. yP< .05 versus native trachea at the same time
point.G
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Sbehavior. All matrices could be stored after the engineering
process in PBS for at least 2 months without losing their
characteristics.
In Vivo Evaluation
In both allotransplantation and xenotransplantation
models, the bioengineered matrices displayed no signs of bi-
oincompatibility in terms of hyperacute, acute, or chronic
rejection; macroscopic inflammatory response; or health im-
pairment during the study period. After 30 days of implanta-
tion, the bioengineered matrices showed a significantly (P<
.01) lower inflammatory reaction in both models compared
with that seen in control tracheas, which became partially
necrotic. There was no detectable SLA antibody in recipient
pigs or an increase in IgM or IgG levels in recipient mice.
The expression of P-selectin was significantly greater in
animals receiving control tracheas than in those receiving
the bioengineered matrices (P< .01; Tables 3 and 4 and
Figure 5).
DISCUSSION
By contrast with other successful organ replacements,
which take place in sterile mesenchymal environments (eg,
the liver, kidney, and heart), the airway represents an inter-
face between the mammal and the external environment.
Unsurprisingly, its mucosa holds immunologically active
cells playing a key role in airway transplantation,12-15 andThe Journal of Thoracic and Cthese contribute to acute allograft rejection, requiring high-
dose immunosuppression.9,10 Inevitably, and given that by
contrast with other organ transplants tracheal replacement
is not a life-saving procedure,1 a completely nonimmuno-
genic tracheal allograft with preserved functional and me-
chanical characteristics represents a necessary ideal for
organ replacement.
The present results demonstrate that the DEM process is
a simple and effective method to bioengineer not only
in vitro7 but also in vivo tracheal matrices lacking any
MHC antigens while maintaining a structural integrity sim-
ilar to that of native tracheas and, most importantly, of suf-
ficient length to have potential clinical application. In
contrast to other replacement methods, such as chemical
fixation, cryopreservation, or lyophilization,13,15,16 this study
presents evidence that the time needed to constantly obtain
a nonimmunogenic graft is around 35 days or 17 cycles and
that this length of processing does not affect their mechanical
properties.
Although all epithelial, interstitial, muscle, and gland cells
disappeared after the 17 DEM cycles, some chondrocyte nu-
clei remained. The fact that they were unable to trigger any
immunologic response might be explained by the fact that
chondrocyte antigens are expressed only on their mem-
branes and not on their nuclei. On the contrary, such nuclei
might even have a positive effect on the biocompatibility
of the matrices and the preservation of their excellentFIGURE 5. A, High P-selectin expression on epithelial cells in small vessels of graft surrounding tissue in animals receiving native trachea. (Original mag-
nification 3100.) B, Low P-selectin expression on epithelial cells in small vessels of graft surrounding tissue in animals receiving bioengineered matrices.
(Original magnification 3100.) The term native trachea represents natural untreated tracheas harvested from healthy animals.ardiovascular Surgery c Volume 138, Number 3 591
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trachea.17,18 Interestingly, the immunologic and mechanical
characteristics of the matrices remained unaffected by a
2-month storage in PBS (containing 1% antibiotic and anti-
mycotic, at 4C). Moreover, higher DEM cycles (>17) are to
be avoided because they worsen the mechanical properties
of the matrices to such an extent that implantation could
be jeopardized. Undoubtedly, the DEM-generated matrices
resemble normal trachea far more than those generated by
using our previously reported protocols.5
To confirm the nonimmunogenic properties of the DEM-
generated matrices, we implanted them in HLA-unmatched
pigs and mice, mimicking allotransplantation and xenotrans-
plantation settings. Implants were left over a period of 30
days without immunosuppression. They displayed no histo-
logic signs of local or graft rejection and significantly less in-
flammatory reaction and activation of adhesion molecules
(eg, P-selectin) or expression of SLA antibodies when com-
pared with control or untreated tracheas during the study pe-
riod. One possible contributory factor to avoidance of
hyperacute and acute rejection is the lack of an immediate
dedicated blood supply, although vessels were seen to
grow into the implanted tissue with time.
In conclusion, our findings suggest that 17 cycles or
around 35 days of DEM are necessary to bioengineer a tra-
cheal tubular matrix that is structurally and mechanically
similar to native trachea. We show that higher cycles should
be avoided to maintain mechanical force and strength. The
immunologic ignorance resulting from this procedure avoids
allorejection and xenorejection in the present animal models,
and therefore there is no need for immunosuppression. We
believe this protocol opens the door to the creation of clini-
cally functional, fully tissue-engineered airway replace-
ments in the near future.
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Discussion
Dr Sebastien Gilbert (Pittsburgh, Pa). First, I would like to
congratulate you and your team for your contribution to the excit-
ing field of airway replacement and regeneration.
I have 3 questions. First, in addition to uniaxial loading, have
you looked at the pressure-diameter response of the grafts or the
ability of the graft to withstand negative intraluminal pressure with-
out collapsing?
Dr Jungebluth. That is a very interesting point. We have not
done it until now but are currently in the process of doing so.
DrGilbert. Second, what effect, if any, does the 35-day, 17-cycle
detergent preparation have on the collagen fiber integrity and the gly-
cosaminoglycan content of the extracellular matrix of the trachea?
Dr Jungebluth. Actually, we did not check it immediately, but
the mechanical strain test showed that this quiet and soft and gentle
treatment actually did not have a strong effect on the mechanical
properties of this tracheal matrix if you just continued under 17 cy-
cles, but I guess it is a critical point that if you continue above 17
cycles, then you will lose the strength and the strain of this matrix.
Dr Gilbert. Finally, what are your thoughts on the relative im-
portance of cartilage and airway epithelium in the immunogenicity
of decellularized tracheal grafts?
Dr Jungebluth. I did not get it. Once again, please.
Dr Gilbert. You showed some pathology slides looking at car-
tilage after 17 detergent cycles, and you made a point to highlight
that there are probably no viable chondrocytes. Do you think thegery c September 2009
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cellular components?
Dr Jungebluth. That is a very interesting question. At this point,
we just looked for the antigenicity and for the strainability. Cur-
rently, we are investigating seeding this matrix again with isolated
cells, and we guess that now we can concentrate on the epithelial
problem with this matrix. Until now, we just finished the mechan-
ical and the antigenicity part, but we are still in the process.
Dr Macchiarini. Just to answer your last question, the role of
cartilage in this model is a minor one. It is true that there were
a few nuclei left, but that did not play any role in the immunoge-
nicity of these grafts when implanted. Therefore I think that if
you have a matrix that still has some vital cartilage, this will not
play a role in the rejection process simply because they are not
vascularized or they are not as vascularized as the internal part
of the trachea.
Dr Robert J. Cerfolio (Birmingham, Ala). First, I congratulate
Dr Macchiarini for the all the wonderful work he has accomplished
in this field. This is such a bad clinical problem. We all see patients
who have had stents put in for benign disease and then we end up
taking them out. We have patients who have had tracheal resections
who come back with anastomotic strictures and problems.
I noticed you are out 30 days. My question to you regards the
future. How much longer are you going to follow these patients
and evaluate for tracheomalacia after implantation, and how far
away are we from being able to pull this off a shelf and put it
into a human being? That would be just fantastic.
DrMacchiarini. Probably he is able to answer more than I, but I
just wanted to thank you for the nice comment.The Journal of Thoracic andWe are in the process of generating a bioreactor in which we will
be able to reseed the trachea with autologous cells—I mean chon-
drocytes—and we succeeded also in reseeding the internal surface
of the trachea with respiratory cells. Hopefully we will present this
next year or in 2 years at this congress.
Coming to your questions, we are now in the process of having
one potential patient who would need a replacement. After the eth-
ical commission and so forth, what we did is take off cartilage from
the nasal septum and from the respiratory cells of the trachea and
put it in culture, and therefore we needed to reseed a donor trachea
that was treated with the DEM procedures. This last process takes
approximately 1 week. Harvesting the donor, depending on the do-
nor pool, and then preparing these cycles takes approximately 11ˇ/2
months. Therefore it would be an elective procedure that we can
prepare, at best, for not only the implantation but even for the char-
acteristics of the graft. I think that 1 to 2 months will be fine to have
an ideal individualized human trachea.
Dr Yolonda L. Colson (Boston, Mass). My concern would be
ciliary clearance. Because there is not anything that looks like cilia,
how are you going to get it to clear the secretions, or do you think it
is going to regrow and repopulate across it?
Dr Macchiarini. That is a wonderful question. Again, hope-
fully, we will present the data. We went a step further and per-
formed orthotopic transplantation of 6 cm in pigs in which we
showed as soon as day 4 that there were ciliary activities. The Bos-
ton and Toronto group showed clearly that as long as you have
a 4-cm graft, there will be some migration of adherent cells. Six
centimeters is clinically more important than 4 cm, but I do not
think that will change this migration capacity.Cardiovascular Surgery c Volume 138, Number 3 593
